GlucoTrack, Inc. (NASDAQ:GCTK)

GlucoTrack, Inc. GCTK

Healthcare - Medical - Instruments & Supplies - NASDAQ - IL

Watchlist

$ 0.2712

-12.5 %

$ 1.57 M

Market Cap

-0.12

P/E

1. INTRINSIC VALUE

GlucoTrack, Inc., a medical device company, designs, develops, and commercializes non-invasive glucose monitoring devices for use by people suffering from diabetes and pre-diabetics in Israel and internationally. It develops GlucoTrack glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Or Yehuda, Israel.[ Read More ]

The intrinsic value of one GCTK stock under the base case scenario is HIDDEN Compared to the current market price of 0.271 USD, GlucoTrack, Inc. is HIDDEN

GCTK Intrinsic Value
HIDDEN

SHOW

2. FUNDAMENTAL ANALYSIS

Price Chart GCTK

FINANCIALS

Annual
Quarterly

0 REVENUE

Growth Rates

1Year 0.00%

3Years 0.00%

5Years 0.00%

7Years 0.00%

10Years 0.00%

-7.1 M OPERATING INCOME

Growth Rates

1Year -60.29%

3Years -48.40%

5Years -15.85%

7Years -12.33%

10Years -12.84%

-7.1 M NET INCOME

Growth Rates

1Year -60.02%

3Years -38.08%

5Years -1.11%

7Years -3.95%

10Years 3.17%

-6.56 M OPERATING CASH FLOW

Growth Rates

1Year -75.86%

3Years -23.27%

5Years -6.04%

7Years -3.06%

10Years -7.38%

0 INVESTING CASH FLOW

Growth Rates

1Year 0.00%

3Years 25.99%

5Years 14.87%

7Years 10.41%

10Years 7.18%

8.73 M FINANCING CASH FLOW

Growth Rates

1Year 0.00%

3Years -12.45%

5Years 11.96%

7Years 8.49%

10Years 5.61%

0 REVENUE

Growth Rates

1Year 0.00%

3Years 0.00%

5Years 0.00%

7Years 0.00%

10Years 0.00%

0 OPERATING INCOME

Growth Rates

1Year -60.29%

3Years -48.40%

5Years -15.85%

7Years -12.33%

10Years -12.84%

-4.49 M NET INCOME

Growth Rates

1Year -60.02%

3Years -38.08%

5Years -1.11%

7Years -3.95%

10Years 3.17%

-1.91 M OPERATING CASH FLOW

Growth Rates

1Year -75.86%

3Years -23.27%

5Years -6.04%

7Years -3.06%

10Years -7.38%

-12 K INVESTING CASH FLOW

Growth Rates

1Year 0.00%

3Years 25.99%

5Years 14.87%

7Years 10.41%

10Years 7.18%

580 K FINANCING CASH FLOW

Growth Rates

1Year 0.00%

3Years -12.45%

5Years 11.96%

7Years 8.49%

10Years 5.61%

Balance Sheet Decomposition GlucoTrack, Inc.

4.9 M ASSETS
1.71 M LIABILITIES

Current Assets	4.87 M
Cash & Short-Term Investments	4.49 M
Receivables	0
Other Current Assets	376 K
Non-Current Assets	37 K
Long-Term Investments	0
PP&E	27 K
Other Non-Current Assets	10 K

Current Liabilities	1.51 M
Accounts Payable	839 K
Short-Term Debt	0
Other Current Liabilities	673 K
Non-Current Liabilities	196 K
Long-Term Debt	196 K
Other Non-Current Liabilities	0

EFFICIENCY

Earnings Waterfall GlucoTrack, Inc.

Revenue	0
Cost Of Revenue	13 K
Gross Profit	-13 K
Operating Expenses	7.1 M
Operating Income	-7.1 M
Other Expenses	-7 K
Net Income	-7.1 M

RATIOS

0.00% GROSS MARGIN

Averages

1Year 0.00%

3Years 0.00%

5Years 15.11%

7Years 4.58%

10Years 18.06%

0.00% OPERATING MARGIN

Averages

1Year 0.00%

3Years 0.00%

5Years 335.85%

7Years 2644.12%

10Years 2872.00%

0.00% NET MARGIN

Averages

1Year 0.00%

3Years 0.00%

5Years -336.86%

7Years -2696.94%

10Years -1885.75%

-221.99% ROE

Averages

1Year -221.99%

3Years -220.78%

5Years -88.43%

7Years -20.88%

10Years -7.46%

-144.69% ROA

Averages

1Year -144.69%

3Years -130.72%

5Years -138.17%

7Years -326.51%

10Years -273.24%

-209.37% ROIC

Averages

1Year -209.37%

3Years -198.84%

5Years -170.17%

7Years -97.26%

10Years -107.97%

FREE CASH FLOW ANALYSIS

Free Cash Flow Analysis GlucoTrack, Inc.

Net Income	-7.1 M
Depreciation & Amortization	13 K
Capital Expenditures	0
Stock-Based Compensation	281 K
Change in Working Capital	190 K
Others	78 K
Free Cash Flow	-6.56 M

3. WALL STREET ANALYSTS ESTIMATES

Wall Street Analysts Price Targets GlucoTrack, Inc.

GCTK has no price targets from Wall Street.

4. DIVIDEND ANALYSIS

0.00% DIVIDEND YIELD

0 USD DIVIDEND PER SHARE

5. COMPETITION

NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics.

0 USD

NXGL

Overvalued 100.00%

Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and internationally.

5.14 USD

AVGR

Undervalued 550.50%

Sharps Technology Inc., a medical device company, researches, designs, develops, manufactures, distributes, and sells safety syringe products in the United States.

0.231 USD

STSS

Overvalued 91.28%

Innovative Eyewear, Inc. develops and sells smart eyeglasses and sunglasses. The company's flagship product is Lucyd Lyte glasses that enable the wearer to listen to music, take and make calls, and use voice assistants to perform various smartphone tasks hands-free.

0 USD

LUCY

Overvalued 100.00%

Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States.

0.103 USD

POAI

Overvalued 85.00%

Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space.

0.219 USD

MBOT

Overvalued 76.34%

Pro-Dex, Inc. designs, develops, and manufactures powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.

0.179 USD

PDEX

Overvalued 99.61%

Meihua International Medical Technologies Co., Ltd. engages in the manufacture and marketing of medical consumables in the People's Republic of China.

0 USD

MHUA

Overvalued 100.00%

6. Ownership

Insider Ownership GlucoTrack, Inc.

Summary
Transactions

Sold

0-3 MONTHS

0 USD 0

3-6 MONTHS

0 USD 0

6-9 MONTHS

0 USD 0

9-12 MONTHS

0 USD 0

Bought

0 USD 0

0-3 MONTHS

891 K USD 2

3-6 MONTHS

230 K USD 1

6-9 MONTHS

0 USD 0

9-12 MONTHS

Date	Value	Insider	Amount	Avg Price
4 months ago Jul 01, 2024	Bought 683 K USD	SYCOFF DREW director, 10 percent owner:	+ 138000	4.95 USD
4 months ago Jul 01, 2024	Bought 208 K USD	Goode Paul Chief Executive Officer	+ 42000	4.95 USD
6 months ago Apr 22, 2024	Bought 230 K USD	SYCOFF DREW director, 10 percent owner:	+ 182539.6	1.26 USD
7 years ago Mar 08, 2017	Bought 1 M USD	Darivoff Philip Director	+ 222223	4.5 USD
7 years ago Mar 08, 2017	Bought 1.72 M USD	Darivoff Philip Director	+ 222223	7.75 USD
7 years ago Mar 08, 2017	Bought 4.5 K USD	Darivoff Philip Director	+ 1000	4.5 USD
7 years ago Nov 30, 2016	Bought 300 K USD	Darivoff Philip Director	+ 66667	4.5 USD
7 years ago Nov 30, 2016	Bought 517 K USD	Darivoff Philip Director	+ 66667	7.75 USD
7 years ago Nov 30, 2016	Bought 1.35 K USD	Darivoff Philip Director	+ 300	4.5 USD

7. News

Glucotrack, Inc. Announces Closing of $10.0 Million Public Offering and Concurrent Private Placement Converting $4.0 in Outstanding Debt Rutherford, NJ., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced the closing of a “best efforts” public offering of 2,437,340 shares of common stock and 4,756,900 pre-funded warrants, with each share of common stock and each pre-funded warrant accompanied by (i) a series A common warrant to purchase one (1) share of common stock at an exercise price of $1.81 per share and (ii) a series B common warrant to purchase one (1) share of common stock at an exercise price of $1.81 per share. The combined offering price of each share of common stock together with the accompanying series A and series B common warrants is $1.39, and the combined offering price of each pre-funded warrant together with the accompanying series A and series B common warrants is $1.389. The gross proceeds of the public offering were approximately $10 million before deducting placement agent fees and offering expenses. globenewswire.com - 2 days ago

GLUCOTRACK TO PRESENT AT 2024 BIOFUTURE CONFERENCE Continuous blood glucose monitor to be among 100+ future-focused presentations at industry investor conference Rutherford, NJ, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it will participate in the 2024 BioFuture Conference, to be held at Cure in New York City from October 28-30, 2024. Paul V. Goode, President & Chief Executive Officer of Glucotrack, will present on Tuesday, October 29, 2024, at 11:00 AM ET and will hold one-on-one meetings. globenewswire.com - 3 weeks ago

GLUCOTRACK ANNOUNCES ORAL & POSTER PRESENTATIONS AT THE 2024 DIABETES TECHNOLOGY MEETING Updated preclinical data for the continuous blood glucose monitor to be presented at major diabetes technology conference globenewswire.com - 1 month ago

JOHN BALLANTYNE, FORMER BIOTECHNOLOGY EXECUTIVE, JOINS THE GLUCOTRACK BOARD OF DIRECTORS Biotech veteran joins Glucotrack's Board to support bringing novel continuous blood glucose monitoring technology to people with diabetes globenewswire.com - 2 months ago

Glucotrack's Innovative Blood Glucose Monitoring Concept Resonates with Patients with Diabetes, According to New Survey Presented at Association of Diabetes Care and Education Specialists (ADCES) 2024 Annual Conference Glucotrack ADCES poster highlights over 50% of surveyed diabetes patients are open to new Continuous Blood Glucose Monitor concept globenewswire.com - 3 months ago

GLUCOTRACK ANNOUNCES POSTER PRESENTATION ON CONTINUOUS BLOOD GLUCOSE MONITOR SURVEY DATA AT THE ASSOCIATION OF DIABETES CARE AND EDUCATION SPECIALISTS (ADCES) 2024 ANNUAL CONFERENCE Market research data shows interest in additional glucose monitoring options for people with diabetes who use insulin Rutherford, NJ, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that an emerging science industry poster will be presented at the Association of Diabetes Care and Education Specialists (ADCES) 2024 Annual Conference to be held August 9-12, 2024 in New Orleans, LA. The Glucotrack poster will present market research data on the acceptance of the Company's Continuous Blood Glucose Monitor (CBGM) concept among people with type 1 and type 2 diabetes. globenewswire.com - 3 months ago

GLUCOTRACK ANNOUNCES THE APPOINTMENT OF ANDY BALO TO BOARD OF DIRECTORS Diabetes industry veteran joins Glucotrack's Board to support bringing novel continuous blood glucose monitoring technology to people with diabetes globenewswire.com - 4 months ago

GLUCOTRACK REPORTS SUCCESSFUL COMPLETION OF FIRST REPORTED LONG-TERM PRECLINICAL STUDY OF ITS EPIDURAL GLUCOSE MONITORING SENSOR Completion of the novel epidural continuous glucose monitoring study confirms its potential for providing simplified disease management for patients with painful diabetic neuropathy globenewswire.com - 5 months ago

GLUCOTRACK TO PRESENT IN THE JUNE 2024 SIDOTI SMALL CAP CONFERENCE Rutherford, NJ, June 10, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it will participate in the Sidoti Small Cap Investor Conference. globenewswire.com - 5 months ago

GLUCOTRACK ANNOUNCES 90-DAY PRECLINICAL STUDY RESULTS THAT DEMONSTRATE SUSTAINED ACCURACY OF ITS IMPLANTABLE CONTINUOUS BLOOD GLUCOSE MONITOR Highly accurate continuous blood glucose monitor demonstrates Mean Absolute Relative Difference (MARD) of 4.7% at Day 90 globenewswire.com - 5 months ago

GLUCOTRACK'S EPIDURAL GLUCOSE MONITORING SENSOR DEMONSTRATES SUCCESSFUL 30-DAY SAFETY & PERFORMANCE IN LONG-TERM PRECLINICAL STUDY Promising results support the potential of epidural glucose monitoring for simplified disease management for patients with painful diabetic neuropathy globenewswire.com - 6 months ago

GLUCOTRACK ANNOUNCES REVERSE STOCK SPLIT 1-for-5 reverse stock split to become effective as of the opening of trading on May 20, 2024 Rutherford, NJ, May 15, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it will effect a 1-for-5 reverse stock split (the “Reverse Stock Split”) of its issued and outstanding common stock (the “Common Stock”), effective with the opening of trading on Monday, May 20, 2024. Glucotrack's Common Stock will continue to trade on the Nasdaq Capital Market (“Nasdaq”) under the symbol “GCTK”. globenewswire.com - 6 months ago

8. Profile Summary

GlucoTrack, Inc. GCTK

COUNTRY IL

INDUSTRY Medical - Instruments & Supplies

MARKET CAP $ 1.57 M

Dividend Yield 0.00%

Description GlucoTrack, Inc., a medical device company, designs, develops, and commercializes non-invasive glucose monitoring devices for use by people suffering from diabetes and pre-diabetics in Israel and internationally. It develops GlucoTrack glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Or Yehuda, Israel.

Contact 8 Ariel Sharon Street, Or Yehuda, 7760049 https://www.glucotrack.com

IPO Date April 25, 2013

Employees 6

Officers Mr. Mark Tapsak Ph.D. Vice President of Technology Ms. Drinda Benjamin Vice President of Marketing Mr. James S. Cardwell Chief Financial Officer Mr. Paul V. Goode Ph.D. Chief Executive Officer, President & Director Mr. Avner Gal MBA, MSc.EE Co-Founder, Chairman Emeritus, Consultant and Member of Scientific & Clinical Advisory Board Mr. David Malka BA Co-Founder Mr. James P. Thrower Ph.D. Vice President of Engineering

Price Chart GCTK

GlucoTrack, Inc. GCTK

Premium Plan

Unlimited Plan